Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Multi-gene panel testing in breast cancer patients

PROVIDER: PRJNA820693 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18502500_1.fastq.gz	Fastqsanger.gz
	SRR18502500_2.fastq.gz	Fastqsanger.gz
	SRR18502501_1.fastq.gz	Fastqsanger.gz
	SRR18502501_2.fastq.gz	Fastqsanger.gz
	SRR18502502_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 128

Similar Datasets

Homo sapiens

Project description:Cancer Multi-Gene Panel Testing with Genexus Sequencer

| PRJDB20670 | ENA

Project description:Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis

| PRJNA927294 | ENA

Homo sapiens

Project description:Human breast cancer gene panel sequencing in NTM patients

| PRJNA431897 | ENA

Project description:Germline panel sequencing of breast cancer patients

| PRJNA510917 | ENA

undefined

Project description:Gene panel sequencing male breast cancer

| PRJEB57620 | ENA

Transcriptional analysis of 12 breast cancer patients

Project description:Targeted gene expression on 12 breast cancer patients using the human panCancer Immune panel (NanoString Technologies)

2022-02-09 | GSE180370 | GEO

Multi-dimensional genomic analysis in breast cancer patients

Project description:Multi-dimensional genomic analysis identifies a class of breast cancer patients with high metastatic outcome and differential response to chemotherapeutic drugs The application of multi-dimensional genomic analyses might provide a more refined risk assessment of breast tumor aggressiveness and improve the selection of patients for personalized medicine. Our study demonstrates the feasibility of using CNAs to predict patient outcome. In combination with gene expression profiles, the clinical implication for such prognostic assays is the identification of breast cancer patients at different risks and sensitivities to chemotherapeutic drugs. Keywords: survival time

2009-05-05 | GSE10099 | GEO

Mkango2019 - Dynamics of Breast Cancer under DifferentRates of Chemoradiotherapy

Project description:Dynamics of Breast Cancer under Different Rates of Chemoradiotherapy. Mkango SB1, Shaban N1, Mureithi E1, Ngoma T2. Author information 1 Department of Mathematics, University of Dar es Salaam, P.O. Box 35062, Dar es Salaam, Tanzania. 2 Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, P.O. Box 65000, Dar es Salaam, Tanzania. Abstract A type of cancer which originates from the breast tissue is referred to as breast cancer. Globally, it is the most common cause of death in women. Treatments such as radiotherapy, chemotherapy, hormone therapy, immunotherapy, and gene therapy are the main strategies in the fight against breast cancer. The present study aims at investigating the effects of the combined radiotherapy and chemotherapy as a way to treat breast cancer, and different treatment approaches are incorporated into the model. Also, the model is fitted to data on patients with breast cancer in Tanzania. We determine new treatment strategies, and finally, we show that when sufficient amount of chemotherapy and radiotherapy with a low decay rate is used, the drug will be significantly more effective in combating the disease while health cells remain above the threshold. Copyright © 2019 Sara B. Mkango et al.

2020-01-20 | MODEL1912120005 | BioModels

RNA-Seq of ex vivo culture of circulating breast tumor cells

Project description:Analyses of circulating tumor cells (CTC) cultured from blood of patients with cancer may allow individualized testing for susceptibility to therapeutic regimens. We established ex vivo cultures of CTCs from six patients with metastatic estrogen receptor-positive breast cancer and performed RNA-Seq on those cultures. One sample each from six metastatic estrogen receptor positive breast cancer patients

2014-07-11 | E-GEOD-55807 | biostudies-arrayexpress

OncoScan analysis to investigate CNV in breast tumors developed by ATM mutation carriers

Project description:The ataxia telangiectasia-mutated (ATM) gene is a moderate-risk breast cancer susceptibility gene; germline loss-of-function variants are found in up to 3% of hereditary breast and ovarian cancer (HBOC) families who undergo genetic testing. So far, no clear molecular features of breast tumors occuring in ATM deleterious variant carriers have been described, but identification of an ATM-associated tumors signature may help patients' management. To characterize hallmarks of ATM-associated tumors, absolute copy number variation and loss of heterozygosity profiles were obtained from the OncoScan SNP array.

2018-05-01 | GSE111711 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data